[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641956":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":19,"studyPopulation":19,"armGroups":30,"interventions":47,"overallOfficials":19,"centralContacts":56,"locations":62,"responsibleParty":78,"collaborators":19,"id":80,"slug":19,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":19,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":19,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":19,"overallStatus":65,"whyStopped":19,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Split, School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":19},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Change in Transepidermal Water Loss (TEWL)","Skin barrier function will be assessed by measuring transepidermal water loss using a Tewameter TM 300 probe. Values will be expressed in g\u002Fm²\u002Fh","Assessments will be performed on 1st, 2nd, 3rd, 4th, 8th and 9th day of the trial (baseline measurements and change from baseline assessment).",{"measure":14,"description":15,"timeFrame":12},"Change in Skin Hydration","Hydration of the stratum corneum will be assessed using a Corneometer CM 825 probe.",{"measure":17,"description":18,"timeFrame":12},"Change in Skin Erythema","Skin erythema will be assessed using a Mexameter MX 18 probe.",null,{"allocation":21,"interventionModel":22,"interventionModelDescription":23,"primaryPurpose":24,"observationalModel":19,"timePerspective":19,"maskingInfo":25},"RANDOMIZED","PARALLEL","This is a randomized, placebo-controlled, intra-individual forearm study in which each participant will receive both topical treatments simultaneously. One forearm will be treated with the cream containing Acetyl Hexapeptide-37, while the contralateral forearm will be treated with placebo. Skin barrier disruption will be induced at the application sites using the tape-stripping method. An additional tape-stripped untreated skin site will serve as a control for spontaneous skin barrier recovery.","TREATMENT",{"masking":26,"maskingDescription":19,"whoMasked":27},"DOUBLE",[28,29],"PARTICIPANT","OUTCOMES_ASSESSOR",[31,37,43],{"label":32,"type":33,"description":34,"interventionNames":35},"Active treatment","EXPERIMENTAL","One forearm will be treated with the peptide-based cream containing Acetyl Hexapeptide-37. The treated forearm (left or right) will be assigned according to the randomization protocol.",[36],"Other: Acetyl Hexapeptide-37",{"label":38,"type":39,"description":40,"interventionNames":41},"Placebo treatment","PLACEBO_COMPARATOR","The other forearm will be treated with a placebo ointment. The allocation of the treatment (left or right forearm) will be determined according to the randomization protocol.",[42],"Other: Placebo",{"label":44,"type":45,"description":46,"interventionNames":19},"Untreated Control Site","NO_INTERVENTION","A designated skin site on either forearm will undergo tape-stripping to induce skin barrier disruption but will not receive any topical treatment. This site will serve as a control for natural skin barrier recovery.",[48,52],{"type":6,"name":49,"description":50,"armGroupLabels":51,"otherNames":19},"Acetyl Hexapeptide-37","The emollient cream contains Acetyl Hexapeptide-37 as the active ingredient and is applied topically to designated skin areas on the forearm. Skin barrier disruption is induced prior to application using the tape-stripping method. Procedure will be performed on healthy, intact skin according to randomization protocol",[32],{"type":6,"name":53,"description":54,"armGroupLabels":55,"otherNames":19},"Placebo","The emollient cream without the peptide is applied topically to designated skin areas on the forearm. Skin barrier disruption is induced prior to application using the tape-stripping method. Procedure will be performed on healthy, intact skin according to randomization protocol",[38],[57],{"name":58,"role":59,"phone":60,"phoneExt":19,"email":61},"Josipa Bukić","CONTACT","+385917933753","jbukic@mefst.hr",[63],{"facility":64,"status":65,"city":66,"state":19,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"University of Split School of Medicine","RECRUITING","Split","21000","Croatia","HR",{"type":71,"coordinates":72},"Point",[73,74],16.43915,43.50891,{"lat":74,"lon":73},[77],{"name":58,"role":59,"phone":60,"phoneExt":19,"email":61},{"type":79,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100641956",false,"NCT07614698","Evaluation of a Peptide Cream on the Forearm Skin Recovery of Healthy Volunteers","Evaluation of the Efficacy of a Topical Formulation Containing Acetyl Hexapeptide-37 on Skin Barrier Recovery of the Forearm After Controlled Damage Using the Tape-stripping Method","Inclusion Criteria:\n\n* healthy volunteers who gave written informed consent\n\nExclusion Criteria:\n\n* skin disease\n* skin damage on measurement sites\n* use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial\n* use of emollients three days prior the inclusion in the trial\n* non-adherence to the trial protocol\n* exposure to artificial and excessive natural ultraviolet (UV) radiation\n* pregnancy or breastfeeding\n* immunosuppression\n* allergic or irritant reactions to the constituents of the cream",true,"ALL","18 Years","50 Years",{"count":91,"type":92},30,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to evaluate the efficacy of a topical peptide-based formulation containing Acetyl Hexapeptide-37 in promoting skin barrier recovery after controlled disruption in healthy adult participants.\n\nThe main questions it aims to answer are:\n\n* Does the peptide cream speed up the recovery of the skin barrier after it has been slightly damaged with tape-stripping method?\n* How does the peptide cream compare to a placebo (a cream with no active ingredient) in improving skin hydration and reducing redness?\n\nResearchers will compare the peptide cream to a placebo to assess its effects on skin barrier recovery\n\nParticipants will:\n\n* Undergo controlled disruption of the skin barrier on the volar forearm using the tape-stripping method.\n* One forearm will receive the peptide-based cream containing Acetyl Hexapeptide-37, while the other (contralateral) forearm will receive a placebo formulation.\n* Attend scheduled visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema",[98],"Skin Barrier Disruption and Recovery","2026-06-15",{"date":101,"type":102},"2026-06-17","ACTUAL",{"date":104,"type":102},"2026-06-01",{"date":106,"type":92},"2027-01",{"name":5,"class":6},1]